Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

It’s “Full Speed Ahead” For Merck In HCV After $3.85B Idenix Buyout

Jun 09 2014

• By Lisa LaMotta

Related Content

Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset

Nov 21 2011

Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity

Aug 02 2012

Related Companies

Merck & Co., Inc.

Idenix Pharmaceuticals, Inc.

AbbVie Inc.

Johnson & Johnson

Bristol Myers Squibb Company

Gilead Sciences, Inc.

Bayer AG

Amgen, Inc.

Additional Topics

United States Business Strategies Clinical Trials Deals BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window